Meetings, Workshops & Trainings
FDA Safety Communications
FDA Advisory Committee Meetings
Latest Publications & Presentations
Data on angioedema risk among sacubitril-valsartan (SV) users in real-world settings are limited. We sought to evaluate the risk of angioedema among SV new users compared with angiotensin-…
We examined patterns in care for individuals treated for latent TB infection (LTBI) in the US Food and Drug Administration's Sentinel System.
Using administrative claims data, we…